Jasper Therapeutics (NASDAQ:JSPR) Rating Increased to Hold at Wall Street Zen

Jasper Therapeutics (NASDAQ:JSPR) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other analysts have also recently weighed in on JSPR. TD Cowen cut Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Royal Bank Of Canada set a $3.00 price objective on Jasper Therapeutics and gave the company a “sector perform” rating in a report on Friday, May 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Friday, July 17th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Jasper Therapeutics presently has an average rating of “Hold” and a consensus price target of $12.00.

Jasper Therapeutics Trading Down 5.6%

NASDAQ:JSPR opened at $0.69 on Friday. Jasper Therapeutics has a 12-month low of $0.32 and a 12-month high of $3.25. The firm has a market cap of $19.28 million, a PE ratio of -0.21 and a beta of 3.07. The stock has a fifty day moving average price of $0.61 and a 200 day moving average price of $1.00.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.08. Equities analysts forecast that Jasper Therapeutics will post -1.67 EPS for the current year.

Institutional Trading of Jasper Therapeutics

A number of large investors have recently made changes to their positions in the company. Knott David M Jr lifted its stake in Jasper Therapeutics by 5.8% in the fourth quarter. Knott David M Jr now owns 181,389 shares of the company’s stock valued at $332,000 after buying an additional 10,000 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Jasper Therapeutics during the second quarter worth approximately $281,000. ADAR1 Capital Management LLC acquired a new position in shares of Jasper Therapeutics in the 4th quarter valued at $256,000. Quarry LP acquired a new position in shares of Jasper Therapeutics in the 4th quarter valued at $182,000. Finally, XTX Topco Ltd purchased a new stake in Jasper Therapeutics in the 2nd quarter valued at $152,000. 79.85% of the stock is owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.